Correlation Between Cerebrospinal Fluid Beta2-microglobulin and Prognosis of Patients with Acute Myeloid Leukemia Subtype M2 After Chemotherapy

Abstract

Background: The correlation of cerebrospinal fluid beta2-microglobulin (CSF-β2MG) and prognosis of acute myeloid leukemia subtype M2 (AML-M2) receiving chemotherapy is uncertain. We seek to explore the prognostic and predictive value of CSF-β2MG in AML-M2 receiving chemotherapy.Methods: CSF-β2MG levels were detected by immunoturbidimetry in a cohort comprised of 40 AML-M2 patients, 25 of whom were categorized into the effective chemotherapy group (Complete Remission (CR) & Partial Remission (PR) and 15 patients into the ineffective group (Non-response (NR) & Death). The correlations between changes (%) in CSF-β2MG from baseline (change between the pre- and post-chemotherapy) or CSF-β2MG (the absolute levels of post-chemotherapy) and prognosis classifications of AML-M2 were assessed. The best cut-off points were investigated.Results: Levels of CSF-β2MG after chemotherapy and percentage change from baseline was variably presented among AML-M2s and progressively more advanced CSF-β2MG levels were associated with worse prognosis and poor therapeutic outcomes. The optimal cut-off value had the potential to be a predictor of treatment failure, hence the value for auxiliary diagnosis and accurate management.Conclusions: Changes in CSF-β2MG could be used to predict clinical outcomes of chemotherapy in patients with AML-M2. The association between changes in CSF-β2MG and the efficacy of chemotherapy thus becomes clearer but requires further study.